Page 3 - Eric Ribner News Today

Operator: Greetings, and welcome to the Eyenovia Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded.

30.03.2023 - Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining a ...

Nes-Ziona, Israel, March 20, 2023 -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that an independent Data and Safety Monitoring... | March 20, 2023

-Patients’ self-reported depression and wellbeing scores corroborate MADRS efficacy data-Statistically significant improvement in anxiety symptoms offers...

First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically significant

Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first...

LONDON, Dec. 14, 2022 -- Small Pharma Inc. , a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it will provide its... | December 15, 2022

23.11.2022 - NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) - Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet delivery system for use both in combination with its own drug-device therapeutic programs for ...

Brings total to twelve granted patents across the Company’s full portfolio LONDON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT)...

Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major Depressive Disorder Completion...